Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
Yahoo Finance · Sep 2, 2026 · Moderna Inc (MRNA)
TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses Together, the long-term clinical and translational data further strengthen confidence in Transgene’s individualized neoantigen therapeutic vaccine approach and myvac® platform Strasbourg, France & Tokyo, Japan, September 2, 2026, 6:00 p.m. CET –
Not investment advice. Cached headline, not a full reprint.